胰激肽释放酶治疗糖尿病肾病白蛋白尿的临床观察

Clinical Effect Observation of Tablet Pancreatic Kininogenase on Urinary Albumin in the Patients with Diabetic Nephropathy

目的 观察胰激肽释放酶 (TPK)治疗糖尿病肾病白蛋白尿的临床疗效。方法 将 4 8例糖尿病患者根据 2 4h尿白蛋白的排泄率 (UAER)分为早期糖尿病肾病组 (A组 )和临床糖尿病肾病组 (B组 )。两组随机分为A1 、A2 组和B1 、B2 组。A1 、B1 组在与A2 、B2 组同样治疗下 ,加用TPK治疗 3个月 ,观察各组治疗前、后尿白蛋白的变化。结果 A1 、B1 组治疗后 2 4h尿白蛋白明显减少 (P <0 .0 1) ,而A2 、B2 组治疗后较治疗前无明显差异 (P >0 .0 5)。结论 TPK可降低糖尿病尿白蛋白的排泄 。

Objective To observe the clinical efficiency of tablet pancreatic kininogenase (TPK) on urinary albumin in the patients with diabetic nephropathy (DN).Methods According to the urinary albumin excretion rate (UAER) per 24 hours , 48 patients with DN were divided into early stage DN group (A group) and clinical stage DN group(B group). Patients of each group were randomly divided into A1 group , A2 group , B1 group and B2 group .In addition to the base treatment ,TPK was also given to A1 and B1 group for three months .Urinary albumin were determined before and after treatment. Results In A1 and B1 group , urinary albumin per 24 hours were significantly reduced after treatment( P <0.01 ).But in A2 and B2 group , the difference between before and after treating was not significant( P >0.05) .Conclusion The administration of TPK could decrease urinary albumin of DN , it is effective on the treating of DN.